Frailty assessments may help to identify patients at highest risk for treatment-related toxicity, early treatment discontinuation due to toxicity, and...

Multiple myeloma (MM) is characterized by excessive production of monoclonal immunoglobulins (M proteins).

Geriatric assessment (GA)-guided supportive care programs have been successful in improving treatment outcomes for older adults with solid-organ...

Multiple myeloma (MM) is characterized by the clonal expansion of plasma cells and the excretion of a monoclonal immunoglobulin (M-protein), or...

Acquired factor FXIII (FXIII) deficiency can be immune- or non-immune mediated and may cause severe bleeding symptoms. The incidence of acquired FXIII...

Multiple myeloma (MM) is a heterogeneous neoplasm accounting for the second most prevalent hematologic disorder.

The pathogenesis of venous thromboembolism in multiple myeloma is still poorly understood because multiple factors are involved. In particular, the...

Randomised controlled trials comparing the effect of exercise interventions with usual care in adults with a diagnosis of multiple myeloma.

Recent advances in the genomic and molecular characterization of PTCL, with enhanced understanding of pathobiology, have translated into significant...

Multiple Myeloma (MM) is the second most common hematological malignancy and is characterized by clonal expansion of malignant plasma cells in the...

Treatment advances have greatly improved survival, but myeloma is among the worst of all cancers for delayed diagnosis, causing serious morbidities...

Therefore, clinical management is often based on this limited literature and extrapolation of data from the more common, nodal T-cell lymphomas in...